Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating

Why did Tesla shares slump today? What impact will Trump’s tariff deadline have? How will GOP megabill affect clean energy? Why is Qantas facing a major cyberattack? What caused Del Monte Foods bankruptcy? How are AI advancements shaping Amazon stock? Why did Senate narrowly pass Trump’s tax bill?

Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating

finance.yahoo.com/news/morgan-stanley-trims-recursion-rxrx-171524592.html

In This Article:
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of 10 AI stocks that will skyrocket.
Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock. The revision comes in…

This story appeared on finance.yahoo.com, 2025-06-25 17:15:24.